Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247532 | PMC |
| http://dx.doi.org/10.18632/oncotarget.28593 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Targets for Pharmacotherapy of Head and Neck Squamous Cell Carcinomas.
Curr Issues Mol Biol
August 2025
Silesia LabMed, Centre for Research and Implementation, Medical University of Silesia in Katowice, 40-752 Katowice, Poland.
Head and neck squamous cell carcinomas (HNSCCs) represent a heterogeneous group of tumors with a complex molecular profile. Despite therapeutic advances, patient prognosis remains poor, emphasizing the need for more effective treatment strategies. Traditional chemotherapy, with cisplatin and 5-fluorouracil (5-FU), remains the gold standard but is limited by toxicity and tumor resistance.
View Article and Find Full Text PDFAccurate and Rapid Ranking of Protein-Ligand Binding Affinities Using Density Matrix Fragmentation and Physics-Informed Machine Learning Dispersion Potentials.
Chemphyschem
August 2025
Department of Chemistry, Virginia Commonwealth University, Richmond, 23284, VA, USA.
The generalized many-body expansion for building density matrices (GMBE-DM), truncated at the one-body level and combined with a purification scheme, is applied to rank protein-ligand binding affinities across two cyclin-dependent kinase 2 (CDK2) datasets and one Janus kinase 1 (JAK1) dataset, totaling 28 ligands. This quantum fragmentation-based method achieves strong correlation with experimental binding free energies (R = 0.84), while requiring less than 5 min per complex without extensive parallelization, making it highly efficient for rapid drug screening and lead prioritization.
View Article and Find Full Text PDFNew Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies.
Am Soc Clin Oncol Educ Book
June 2025
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
With the rapid introduction of novel breast cancer therapies, recognizing and managing side effects is essential to maintain adherence and improve outcomes. As novel oral endocrine therapies and combination strategies including targeted agents have prolonged progression and in some cases disease-free survival, early recognition and appropriate management of these toxicities is critical to optimize quality of life. Dermatologic adverse events are frequently associated with novel breast cancer therapies including immune checkpoint inhibitors (ICIs), targeted therapies, and antibody-drug conjugates (ADCs).
View Article and Find Full Text PDFBackground: The risk of drug-induced corrected QT interval (QTc) prolongation is an important consideration in clinical decision-making for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). This retrospective analysis described concomitant QTc-prolonging medication use in patients with HR+/HER2- mBC who received first-line (1L) treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus an aromatase inhibitor (AI).
Methods: This retrospective claims analysis utilized the Optum Clinformatics Data Mart database to identify patients with HR+/HER2- mBC who initiated 1L CDK4/6i plus AI treatment between January 2017 and March 2022.